AAAAAA
Results: 51-75/116
Authors:
WILHELM M
KANTARJIAN HM
OBRIEN S
PIERCE S
KEATING MJ
FREIREICH EJ
ESTEY EH
Citation: M. Wilhelm et al., PNEUMONIA DURING REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS WITH AML OR MDS, Blood, 88(10), 1996, pp. 3411-3411
Authors:
WILHELM M
RAMOS CM
OBRIEN S
PIERCE S
KEATING M
TALPAZ M
KANTARJIAN H
Citation: M. Wilhelm et al., EFFECT OF INTERFERON-ALPHA (IFN-A) THERAPY ON BONE-MARROW (BM) FIBROSIS IN CHRONIC MYELOGENOUS LEUKEMIA (CML), Blood, 88(10), 1996, pp. 3537-3537
Authors:
THOMAS D
KANTARJIAN H
KEATING MJ
OBRIEN S
PIERCE S
BERAN M
KOLLER C
FREIREICH E
Citation: D. Thomas et al., ADULT ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) IN FIRST RELAPSE - CHARACTERISTICS, OUTCOME, AND PROGNOSIS WITH SALVAGE THERAPY, Blood, 88(10), 1996, pp. 294-294
Authors:
ESTEY E
THALL P
PIERCE S
FAYAD L
KORNBLAU S
KANTARJIAN H
KEATING M
Citation: E. Estey et al., ASSOCIATION BETWEEN INCREASED BODY-MASS INDEX AND A DIAGNOSIS OF ACUTE PROMYELOCYTIC LEUKEMIA IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA, Blood, 88(10), 1996, pp. 312-312
Authors:
DELIMA M
STROM S
KEATING M
PIERCE S
KANTARJIAN H
FREIREICH E
ESTEY E
Citation: M. Delima et al., SUBSEQUENT CANCER AND RETURN TO WORK IN PATIENTS (PTS) WITH POTENTIALLY CURED AML, Blood, 88(10), 1996, pp. 845-845
Authors:
ESTEY E
THALL P
KANTARJIAN H
KEATING M
PIERCE S
BERAN M
Citation: E. Estey et al., DIAGNOSIS OF RAEB OR RAEB-T, RATHER THAN AML, DOES NOT NEGATIVELY INFLUENCE OUTCOME OF ANTI-AML CHEMOTHERAPY, Blood, 88(10), 1996, pp. 1155-1155
Authors:
ESTEY E
BERAN M
HAYES K
LOVSHE D
KOMBLAU S
PIERCE S
KOLLER C
OBRIEN S
KANTARJIAN H
ANDREEFF M
KEATING M
FREIREICH E
Citation: E. Estey et al., CYTOGENETIC (CG) AND FLUORESCENT IN-SITU HYBRIDIZATION (FISH) ANALYSIS ON COURSE 1 DAY 21 OF CHEMOTHERAPY (CT) FOR NEWLY-DIAGNOSED AML MDS/, Blood, 88(10), 1996, pp. 2245-2245
Authors:
ESTEY E
PIERCE S
Citation: E. Estey et S. Pierce, ROUTINE BONE-MARROW EXAM DURING FIRST REMISSION OF ACUTE MYELOID-LEUKEMIA, Blood, 87(9), 1996, pp. 3899-3902
Authors:
CORTES J
KANTARJIAN H
OBRIEN S
ROBERTSON LE
PIERCE S
TALPAZ M
Citation: J. Cortes et al., RESULTS OF INTERFERON-ALPHA THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA 60 YEARS OF AGE AND OLDER, The American journal of medicine, 100(4), 1996, pp. 452-455
Authors:
ESTEY EH
KANTARJIAN HM
OBRIEN S
KORNBLAU S
ANDREEFF M
BERAN M
PIERCE S
KEATING M
Citation: Eh. Estey et al., HIGH REMISSION RATE, SHORT REMISSION DURATION IN PATIENTS WITH REFRACTORY-ANEMIA WITH EXCESS BLASTS (RAEB) IN TRANSFORMATION (RAEB-T) GIVENACUTE MYELOGENOUS LEUKEMIA (AML)-TYPE CHEMOTHERAPY IN COMBINATION WITH GRANULOCYTE-CSF (G-CSF), Cytokines and molecular therapy, 1(1), 1995, pp. 21-28
Authors:
MARLTON P
KEATING M
KANTARJIAN H
PIERCE S
OBRIEN S
FREIREICH EJ
ESTEY E
Citation: P. Marlton et al., CYTOGENETIC AND CLINICAL CORRELATES IN AML PATIENTS WITH ABNORMALITIES OF CHROMOSOME-16, Leukemia, 9(6), 1995, pp. 965-971
Authors:
ESTEY E
KEATING MJ
PIERCE S
STASS S
Citation: E. Estey et al., CHANGE IN KARYOTYPE BETWEEN DIAGNOSIS AND FIRST RELAPSE IN ACUTE MYELOGENOUS LEUKEMIA, Leukemia, 9(6), 1995, pp. 972-976
Authors:
GHADDAR HM
PIERCE S
REED P
ESTEY EH
Citation: Hm. Ghaddar et al., PROGNOSTIC VALUE OF RESIDUAL NORMAL METAPHASES IN ACUTE MYELOGENOUS LEUKEMIA PATIENTS PRESENTING WITH ABNORMAL KARYOTYPE, Leukemia, 9(5), 1995, pp. 779-782
Authors:
CORTES JE
KANTARJIAN H
OBRIEN S
KEATING M
PIERCE S
FREIREICH EJ
ESTEY E
Citation: Je. Cortes et al., CLINICAL AND PROGNOSTIC-SIGNIFICANCE OF TRISOMY-21 IN ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA AND MYELODYSPLASTIC SYNDROMES, Leukemia, 9(1), 1995, pp. 115-117
Authors:
DALTON JA
BERNARD S
BLAU W
JOHNSTON C
MANN JD
GERMINO B
PIERCE S
TOOMEY T
MOONEY D
CARLSON J
Citation: Ja. Dalton et al., MANAGING CANCER PAIN - CONTENT AND SCOPE OF AN EDUCATIONAL-PROGRAM FOR NURSES WHO WORK IN PREDOMINANTLY RURAL-AREAS, Journal of pain and symptom management, 10(3), 1995, pp. 214-223
Authors:
SACCHI S
KANTARJIAN H
OBRIEN S
COHEN PR
PIERCE S
TALPAZ M
Citation: S. Sacchi et al., IMMUNE-MEDIATED AND UNUSUAL COMPLICATIONS DURING INTERFERON-ALFA THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA, Journal of clinical oncology, 13(9), 1995, pp. 2401-2407
Authors:
PIERCE S
Citation: S. Pierce, THE PURPORTED LINK BETWEEN AGENT ORANGE AND CANCER, Human pathology, 26(6), 1995, pp. 693-694
Authors:
LOEWY R
PIERCE S
Citation: R. Loewy et S. Pierce, LINEAR PRESERVERS OF BALANCED NONSINGULAR INERTIA CLASSES, Linear algebra and its applications, 224, 1995, pp. 483-499
Authors:
CORTES J
OBRIEN SM
PIERCE S
KEATING MJ
FREIREICH EJ
KANTARJIAN HM
Citation: J. Cortes et al., THE VALUE OF HIGH-DOSE SYSTEMIC CHEMOTHERAPY AND INTRATHECAL THERAPY FOR CENTRAL-NERVOUS-SYSTEM PROPHYLAXIS IN DIFFERENT RISK GROUPS OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA, Blood, 86(6), 1995, pp. 2091-2097
Authors:
ESTEY E
PIERCE S
Citation: E. Estey et S. Pierce, NEED FOR ROUTINE BONE MARROWS IN ACUTE MYELOGENOUS LEUKEMIA IN CR, Blood, 86(10), 1995, pp. 1315-1315
Authors:
BERAN M
OBRIEN S
ARBUCK S
PIERCE S
KEATING M
KANTARJIAN H
Citation: M. Beran et al., TOPOTECAN, A TOPOISOMERASE-I INHIBITOR, IS A ACTIVE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA, Blood, 86(10), 1995, pp. 1335-1335
Authors:
BSEISO AW
ALBITAR M
PIERCE S
ESTEY E
Citation: Aw. Bseiso et al., MYELOPEROXIDASE (MPO) STAIN IN AML - IMPACT OF PERCENTAGE OF POSITIVEBLASTS ON CLINICAL OUTCOME, Blood, 86(10), 1995, pp. 2994-2994
Authors:
DELIMA M
GHADDAR H
PIERCE S
ESTEY E
Citation: M. Delima et al., TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) IN PATIENTS AGE 80 YEARS AND ABOVE, Blood, 86(10), 1995, pp. 3008-3008
Authors:
RAVANDIKASHANI F
HAYES K
LOVSHE D
PIERCE S
ESTEY E
Citation: F. Ravandikashani et al., PROGNOSTIC-SIGNIFICANCE OF AN UNSUCCESSFUL CYTOGENETIC ANALYSIS IN NEWLY-DIAGNOSED AML, Blood, 86(10), 1995, pp. 3091-3091
Authors:
KOWALSKI M
PIERCE S
BECK M
Citation: M. Kowalski et al., COMPARISON OF 3 COMMERCIAL PLATELET ANTIBODY SCREENING-TEST KITS, Blood, 86(10), 1995, pp. 3589-3589